NEW search data revealed a 302% increase in UK interest for ‘Mounjaro’, following the NHS's announcement on December 5, of possible Mounjaro prescription delays.

Research conducted by weight-loss programme Second Nature, also showed public demand for ‘Mounjaro’ increased by over 3,450% since the beginning of the year.

The news follows controversy of the medication, which The Forester previously reported and a report of Gloucestershire’s interest in medications such as this.

Second Nature’s research also revealed searches for ‘weight loss jab’ and ‘weight loss drug’ exceeded 275% since December 5.

Mike Gibbs, co-founder of Second Nature, said: "This upcoming weight-loss drug rollout could significantly impact the lives of many who need it. With obesity levels rising and the NHS stretched, weight-loss injections like Mounjaro are considered as potential game-changers. However, access remains limited, and managing expectations around these treatments is vital.

"Weight-loss injections are not a quick-fix solution, and they may not be effective for everyone. It's crucial to consider sustainable approaches to weight management, including balanced diets and regular exercise, alongside medical consultation. Personalised advice ensures that treatment plans are safe, effective, and suitable for your long-term health."

Mounjaro is the brand name of the drug Tirzepatide, which is approved to treat type 2 diabetes, and can also trigger insulin creation and feelings of fullness.

It is recommended for those with a Body Mass Index (BMI) of more than 35 and at least one weight-related illness. The latest health survey for England reports 64% of adults in England were overweight or obese in 2022.

The new rollout plans aim to provide medication to support 220,000 overweight individuals, but this accounts for less than 10% of eligible patients over the next three years.

Further weight loss information can be accessed with your GP and via the NHS website.